Funke-Chambour M - Search Results

1

Multidisciplinary discussion for diagnosis of interstitial lung disease in real life.

Guler SA, Berezowska SA, Christe A, Geiser T, Funke-Chambour M. Guler SA, et al. Swiss Med Wkly. 2016 Jun 1;146:w14318. doi: 10.4414/smw.2016.14318. eCollection 2016. Swiss Med Wkly. 2016. PMID: 27249663 Free article. No abstract available.

2

[Anti-fibrotics as novel therapy for idiopathic pulmonary fibrosis].

Funke-Chambour M, Geiser T. Funke-Chambour M, et al. Ther Umsch. 2016;73(1):25-9. doi: 10.1024/0040-5930/a000751. Ther Umsch. 2016. PMID: 26884217 Review. German.

3

Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment.

Funke-Chambour M, Azzola A, Adler D, Barazzone-Argiroffo C, Benden C, Boehler A, Bridevaux PO, Brutsche M, Clarenbach CF, Hostettler K, Kleiner-Finger R, Nicod LP, Soccal PM, Tamm M, Geiser T, Lazor R. Funke-Chambour M, et al. Respiration. 2017;93(5):363-378. doi: 10.1159/000464332. Epub 2017 Mar 25. Respiration. 2017. PMID: 28343230 Free article.

4

Exhaled breath condensate as a potential biomarker tool for idiopathic pulmonary fibrosis-a pilot study.

Rindlisbacher B, Strebel C, Guler S, Kollár A, Geiser T, Martin Fiedler G, Benedikt Leichtle A, Bovet C, Funke-Chambour M. Rindlisbacher B, et al. J Breath Res. 2017 Nov 29;12(1):016003. doi: 10.1088/1752-7163/aa840a. J Breath Res. 2017. PMID: 28775244 Free article.

5

Pharmakologische und nicht-pharmakologische Therapie der idiopathischen Lungenfibrose.

Schertel A, Funke-Chambour M, Geiser T. Schertel A, et al. Praxis (Bern 1994). 2017 Sep;106(18):999-1006. doi: 10.1024/1661-8157/a002770. Praxis (Bern 1994). 2017. PMID: 28875747 German. No abstract available.

6

Novel insights in cough and breathing patterns of patients with idiopathic pulmonary fibrosis performing repeated 24-hour-respiratory polygraphies.

Schertel A, Funke-Chambour M, Geiser T, Brill AK. Schertel A, et al. Respir Res. 2017 Nov 13;18(1):190. doi: 10.1186/s12931-017-0674-y. Respir Res. 2017. PMID: 29132424 Free PMC article.

7

Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis - a potential biomarker role for LysoPC.

Rindlisbacher B, Schmid C, Geiser T, Bovet C, Funke-Chambour M. Rindlisbacher B, et al. Respir Res. 2018 Jan 10;19(1):7. doi: 10.1186/s12931-018-0714-2. Respir Res. 2018. PMID: 29321022 Free PMC article. Clinical Trial.

8

Idiopathic pulmonary fibrosis in a Swiss interstitial lung disease reference centre.

Guler S, Zumstein P, Berezowska S, Pöllinger A, Geiser T, Funke-Chambour M. Guler S, et al. Swiss Med Wkly. 2018 Jan 4;148:w14577. doi: 10.4414/smw.2018.14577. eCollection 2018. Swiss Med Wkly. 2018. PMID: 29376545 Free article.

9

Medium throughput breathing human primary cell alveolus-on-chip model.

Stucki JD, Hobi N, Galimov A, Stucki AO, Schneider-Daum N, Lehr CM, Huwer H, Frick M, Funke-Chambour M, Geiser T, Guenat OT. Stucki JD, et al. Sci Rep. 2018 Sep 25;8(1):14359. doi: 10.1038/s41598-018-32523-x. Sci Rep. 2018. PMID: 30254327 Free PMC article.

10

Antifibrotics: Shrinking the Box of Therapeutic Uncertainty.

Guler SA, Funke-Chambour M. Guler SA, et al. Respiration. 2019;97(3):202-204. doi: 10.1159/000494275. Epub 2018 Nov 19. Respiration. 2019. PMID: 30453286 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55 results

Search Page

Filters